Adcock Ingram expects headline earnings per share (HEPS) for the six months ended December 2016 to leap between 45% and 49%. Since early 2014, the Bidvest-linked pharmaceuticals group has been a somewhat bitter pill for shareholders to swallow. But it appears to have turned a corner in 2017, with the share price jumping from about R44 a share in late November to about R54 now. The group experienced a nonrecurring capital profit in the interim period resulting from the R407m disposal of part of its Indian business in 2016. This was tempered by certain nonrecurring accounting costs. Results for the six months are expected to be released on or around February 22.

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now